原研机构 |
非在研机构- |
最高研发阶段临床3期 |
首次获批日期- |
最高研发阶段(中国)临床3期 |
特殊审评- |
开始日期2024-07-08 |
申办/合作机构 |
开始日期2024-06-06 |
申办/合作机构 |
开始日期2024-04-30 |
申办/合作机构 |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
中度特应性皮炎 | 临床3期 | 中国 | 2024-04-30 | |
重度特应性皮炎 | 临床3期 | 中国 | 2024-04-30 | |
哮喘 | 临床1期 | 中国 | 2022-02-11 | |
慢性鼻窦炎伴鼻息肉 | 临床申请批准 | 中国 | 2024-01-02 |
研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
---|
临床1期 | IL-4 | IL-13 | 40 | 蓋鑰範構願構築鹽淵壓(鏇鑰積鏇窪夢醖廠艱鏇) = A total of 28 (87.5%) subjects received AK120 treatment and 7 (77.8%) subjects received placebo experienced at least one treatment-emergent adverse event (TEAE). All TEAEs were mild and moderate in severity. 12 (37.5%) subjects experienced at least one treatment-related TEAEs in the AK120 treatment group, and 4 (44.4%) subjects in the placebo group. The most common TEAEs occurred in AK120 treatment group were skin infection (12.5%) and injection site pain (12.5%). There was no death, no serious adverse event (SAE) or treatment-related SAE in the study. 夢壓窪壓觸壓網鹹淵獵 (憲鹹鹹構窪鏇壓鏇壓艱 ) | 积极 | 2023-10-11 | ||
Placebo | |||||||
临床1期 | IL-4 receptor alpha (IL-4Rα) | IL-4 | IL-13 | 40 | 構簾衊淵構艱選廠膚淵(淵積鹹製選衊壓繭廠積) = 襯網觸遞壓繭淵襯淵鏇 簾築餘積構餘餘鏇鬱鏇 (艱夢觸憲糧餘壓鑰構鏇 ) 更多 | 积极 | 2022-09-07 | ||
構簾衊淵構艱選廠膚淵(淵積鹹製選衊壓繭廠積) = 衊顧鑰簾範製淵鏇壓蓋 簾築餘積構餘餘鏇鬱鏇 (艱夢觸憲糧餘壓鑰構鏇 ) 更多 |